Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study)
- 1 December 2009
- journal article
- clinical trial
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 10 (6) , 368-374
Abstract
Long-term adverse events and expenses associated with HAART have led to an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due to its potency and high genetic barrier. This is a 96-week, open-label, randomized study to assess the feasibility of using LPV/r monotherapy in patients with undetectable viral load after being on successful HAART for at least 6 months. Subjects were randomized (1:1) to either switch from HAART to LPV/r monotherapy or to maintain their previous regimen. 60 patients were enrolled. Baseline characteristics were similar in both groups. At Week 96, by intention-to-treat analysis, 24/30 (80.0%) subjects in monotherapy group and 26/30(86.6%) in the control group had a plasma viral load of <80 copies/mL. There was one virologic failure (defined as VL not greater-than 500 copies/mL) in each arm. Genotyping testing identified no resistance-associated mutations. The patient on the monotherapy arm was successfully resuppressed to <80 copies/mL after intensification with tenofovir and lamivudine. No statistically significant differences were found with regard to changes in CD4 counts. One subject in the monotherapy group discontinued due to diarrhea. Five subjects in the control group underwent regimen changes due to drug-related toxicities. Viral load from semen samples collected at the end of follow-up was undetectable on 14/15 patients randomized to monotherapy. Switching from various HAART regimens to LPV/r monotherapy in patients who were virologically suppressed and without a history of previous virologic failure was effective, safe, and well tolerated through 96 weeks.Keywords
This publication has 11 references indexed in Scilit:
- Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week AnalysisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic reviewAIDS, 2009
- A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination TherapyThe Journal of Infectious Diseases, 2008
- Lopinavir/ritonavir monotherapy as maintenance treatment in HIV‐infected individuals with virological suppression: results from a pilot study in BrazilHIV Medicine, 2008
- Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsAIDS, 2008
- The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) TrialAIDS, 2007
- Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in BrazilTherapeutic Drug Monitoring, 2006
- Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral SuppressionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patientsAIDS, 2005
- Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence InstrumentsAIDS Care, 2000